Janssen-Cilag SpA

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.janssen.com/italy

Clinical Trials

A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: PAH medication

First Posted Date: 2020-09-28

Last Posted Date: 2025-03-30

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 186

Registration Number: NCT04567602

Locations: 🇮🇹
Azienda Ospedaliera G. Brotzu, Cagliari, Italy
🇮🇹
ASL2 Lanciano - Vasto - Chieti - Ospedale 'SS Annunziata' di Chieti, Chieti, Italy
🇮🇹
AOU Careggi, Firenze, Italy

and more 27 locations

A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy

Completed

Conditions: Depressive Disorder, Major
Suicidal Ideation

Interventions: Other: No Intervention

First Posted Date: 2020-07-09

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 136

Registration Number: NCT04463108

Locations: 🇮🇹
Ospedale S Francesco d Assisi, Oliveto Citra, Italy
🇮🇹
ASST Spedali Civili Brescia, Brescia, Italy
🇮🇹
Ospedale Santissima Trinità, Cagliari, Italy

and more 21 locations

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis

Completed

Conditions: Psoriasis

Interventions: Drug: Guselkumab

First Posted Date: 2020-06-19

Last Posted Date: 2024-01-05

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 356

Registration Number: NCT04439526

Locations: 🇮🇹
Azienda Ospedaliera Universitaria - OO.RR. San Giovanni di Dio Ruggi d'Aragona, Cava de' Tirreni, Italy
🇮🇹
Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli, Napoli, Italy
🇮🇹
Ospedale San Giovanni di Dio, Cagliari, Italy

and more 35 locations

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Ibrutinib

First Posted Date: 2018-10-25

Last Posted Date: 2022-01-03

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 312

Registration Number: NCT03720561

Locations: 🇮🇹
Div.Clinicizzata EmatologiaconTrapiantodi MidolloOsseo P.O.Rodoligo AOUPoliclinico-Vittorio Emanuele, Catania, Italy
🇮🇹
S.C. Ematologia Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
🇮🇹
Unità Funzionale di Ematologia Azienda ospedaliero-universitaria Careggi, Firenze, Italy

and more 36 locations

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Drug: D/C/F/TAF Fixed-Dose Combination (FDC)

First Posted Date: 2018-07-05

Last Posted Date: 2024-10-14

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 246

Registration Number: NCT03577470

Locations: 🇮🇹
A O Universitaria Senese Ospedale Santa Maria alle Scotte, Siena, Italy
🇮🇹
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy

and more 15 locations

A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs

Completed

Conditions: Spondyloarthritis, Axial and Peripheral

First Posted Date: 2017-04-27

Last Posted Date: 2021-09-30

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 351

Registration Number: NCT03131661

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
🇮🇹
ASST Spedali Civili Brescia, Brescia, Italy
🇮🇹
Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Italy

and more 22 locations

Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)

Completed

Conditions: Human Immunodeficiency Virus

First Posted Date: 2016-10-06

Last Posted Date: 2018-04-24

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 337

Registration Number: NCT02926456

Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Risperidone Long-acting Injectable (LAI) 25 mg
Drug: Risperidone LAI 37.5 mg
Drug: Risperidone LAI 50 mg

First Posted Date: 2013-06-27

Last Posted Date: 2013-06-27

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 347

Registration Number: NCT01888107

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

Completed

Conditions: Human Immunodeficiency Virus; HIV

Interventions: Drug: Darunavir/Ritonavir (DRV/r)
Drug: Efavirenz (EFV)

First Posted Date: 2012-02-29

Last Posted Date: 2013-11-26

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 33

Registration Number: NCT01541085

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients

Phase 2

Completed

Conditions: Human Immunodeficiency Virus 1

Interventions: Drug: Darunavir(DRV)
Drug: Ritonavir
Drug: 2 nucleoside reverse transcriptase inhibitors (NRTIs)

First Posted Date: 2011-07-11

Last Posted Date: 2013-06-27

Lead Sponsor: Janssen-Cilag S.p.A.

Target Recruit Count: 30

Registration Number: NCT01391013

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy